Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:OPTNNASDAQ:RAPPNASDAQ:RGNXNASDAQ:STOK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeOPTNOptiNose$9.60$9.48$4.82▼$19.50$97.22M-0.8865,153 shsN/ARAPPRapport Therapeutics$11.89-3.9%$10.84$6.43▼$29.74$437.71MN/A164,671 shs29,997 shsRGNXREGENXBIO$8.49-0.8%$8.82$5.04▼$15.36$421.09M1.09922,661 shs73,557 shsSTOKStoke Therapeutics$11.61+0.9%$9.97$5.35▼$16.15$635.00M1.09687,323 shs214,381 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceOPTNOptiNose0.00%0.00%0.00%+4.69%-40.19%RAPPRapport Therapeutics+13.79%+13.06%+14.42%+27.63%+1,237,999,900.00%RGNXREGENXBIO+8.91%-1.15%-11.84%+4.39%-33.07%STOKStoke Therapeutics-0.69%-1.29%+22.97%+55.54%-19.68%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationOPTNOptiNose0.7998 of 5 stars1.00.00.04.20.01.70.6RAPPRapport Therapeutics1.4115 of 5 stars3.50.00.00.01.10.00.6RGNXREGENXBIO3.946 of 5 stars3.42.00.04.60.03.30.6STOKStoke Therapeutics3.7134 of 5 stars3.60.00.04.81.10.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceOPTNOptiNose 2.00Hold$9.00-6.25% DownsideRAPPRapport Therapeutics 3.00Buy$32.67174.72% UpsideRGNXREGENXBIO 2.83Moderate Buy$31.63272.32% UpsideSTOKStoke Therapeutics 3.29Buy$23.2099.83% UpsideCurrent Analyst Ratings BreakdownLatest OPTN, RAPP, STOK, and RGNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2025RGNXREGENXBIOChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$52.005/19/2025OPTNOptiNoseHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$9.00 ➝ $9.005/14/2025STOKStoke TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/14/2025STOKStoke TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$47.00 ➝ $35.004/17/2025RGNXREGENXBIOThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$14.00 ➝ $12.004/9/2025STOKStoke TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.004/8/2025RAPPRapport TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Outperform$28.004/8/2025RAPPRapport TherapeuticsCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMkt Outperform(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookOPTNOptiNose$81.86M1.19N/AN/A($11.56) per share-0.83RAPPRapport TherapeuticsN/AN/AN/AN/A$8.35 per shareN/ARGNXREGENXBIO$83.33M5.11N/AN/A$5.24 per share1.62STOKStoke Therapeutics$36.56M17.34N/AN/A$4.32 per share2.69Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateOPTNOptiNose-$35.48M-$3.00N/AN/AN/A-41.16%N/A-27.42%8/6/2025 (Estimated)RAPPRapport Therapeutics-$78.31M-$3.45N/AN/AN/AN/A-25.48%-24.63%8/14/2025 (Estimated)RGNXREGENXBIO-$227.10M-$3.11N/AN/AN/A-100.62%-53.29%-30.84%8/7/2025 (Estimated)STOKStoke Therapeutics-$88.98M$0.7914.72N/AN/A26.33%19.08%15.72%8/5/2025 (Estimated)Latest OPTN, RAPP, STOK, and RGNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025OPTNOptiNose-$0.74-$1.01-$0.27-$1.92$17.70 million$18.51 million5/12/2025Q1 2025RGNXREGENXBIO$0.41$0.12-$0.29$0.12$105.35 million$89.01 million5/8/2025Q1 2025RAPPRapport Therapeutics-$0.77-$0.68+$0.09-$0.68N/AN/A3/26/2025Q4 2024OPTNOptiNose-$0.70-$0.03+$0.67-$0.03$21.02 million$21.47 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthOPTNOptiNoseN/AN/AN/AN/AN/ARAPPRapport TherapeuticsN/AN/AN/AN/AN/ARGNXREGENXBION/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioOPTNOptiNoseN/A0.790.72RAPPRapport TherapeuticsN/A31.0131.01RGNXREGENXBION/A2.932.93STOKStoke TherapeuticsN/A8.418.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipOPTNOptiNose85.60%RAPPRapport TherapeuticsN/ARGNXREGENXBIO88.08%STOKStoke TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipOPTNOptiNose2.30%RAPPRapport TherapeuticsN/ARGNXREGENXBIO12.79%STOKStoke Therapeutics9.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableOPTNOptiNose19010.13 million9.83 millionNot OptionableRAPPRapport TherapeuticsN/A36.50 millionN/AN/ARGNXREGENXBIO37050.16 million43.75 millionOptionableSTOKStoke Therapeutics10054.60 million49.41 millionOptionableOPTN, RAPP, STOK, and RGNX HeadlinesRecent News About These CompaniesStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 17, 2025 | businesswire.comFY2025 EPS Estimates for STOK Reduced by Cantor FitzgeraldJune 16, 2025 | americanbankingnews.comSTOK FY2025 EPS Forecast Lowered by Cantor FitzgeraldJune 16, 2025 | marketbeat.comStoke Therapeutics: Impressive Pipeline And Big BackersJune 16, 2025 | seekingalpha.comAssenagon Asset Management S.A. Sells 391,322 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)June 15, 2025 | marketbeat.comCantor Fitzgerald Predicts STOK FY2026 EarningsJune 10, 2025 | marketbeat.comKangaroo Care Awareness Day celebrated at Stoke Mandeville HospitalJune 10, 2025 | msn.comJong Oranje and Stoke City star is open to transfer: “Of course, I have my ambitions”June 10, 2025 | sports.yahoo.comStoke City confirm next stage of major badge consultationJune 10, 2025 | msn.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)June 10, 2025 | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) Shares Sold by Two Sigma Investments LPJune 9, 2025 | marketbeat.comJane Street Group LLC Sells 318,465 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)June 8, 2025 | marketbeat.comStoke City Secure Youth International Amid Leeds United InterestJune 7, 2025 | therealefl.co.ukFive hours of 'thundery showers' to rock Stoke-on-Trent todayJune 7, 2025 | msn.comBusiness forum will look at how the Stoke-on-Trent and Staffordshire area sells itself to the worldJune 7, 2025 | expressandstar.comCelebrations as Stoke-on-Trent turns 100 years oldJune 7, 2025 | bbc.comLeeds United dealt transfer blow as Stoke City near 'two-year deal' for England youth internationalJune 7, 2025 | yorkshirepost.co.ukHuddersfield Town confirm departure of 125-appearance man as Stoke City snap up former Hull City targetJune 7, 2025 | yorkshirepost.co.ukLive updates as Lancaster Bomber performing Stoke-on-Trent flypastJune 7, 2025 | stokesentinel.co.ukJon Walters opens up on Sorba Thomas transfer tussle as Stoke City make first moveJune 7, 2025 | msn.comMillennium Management LLC Increases Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)June 7, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOPTN, RAPP, STOK, and RGNX Company DescriptionsOptiNose NASDAQ:OPTN$9.60 0.00 (0.00%) As of 05/21/2025OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.Rapport Therapeutics NASDAQ:RAPP$11.89 -0.49 (-3.95%) As of 11:31 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.REGENXBIO NASDAQ:RGNX$8.49 -0.07 (-0.77%) As of 11:32 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.Stoke Therapeutics NASDAQ:STOK$11.61 +0.10 (+0.87%) As of 11:31 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Costco at a Crossroads: Is the Next Move Higher or Lower? AST SpaceMobile's Signal Strengthens as Stock Nears Orbit Oracle Stock Boils Higher, $300 Price Target in Sight 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Which Analyst-Favorite Drone Stock Will Come Out on Top? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
